Current Neuro-Oncology
Volume
24 Number 19
15 October 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 19, 15 October
She
L, Gong X, Su L, Liu C.
Radiotherapy
Plus Temozolomide With or Without Nimotuzumab Against the Newly
Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort
Study.
Oncologist.
2022 Oct 1, 2022:oyac202∟.
Doi: 10.1093/oncolo/oyac202∟.
PMID: 36181764∟.
Observational study. ˍ
Józefacka NM,
Machnikowska-Sokołowska MD, Kołek MF, Gruszczyńska
KJ, Musioł K.
Cognitive
performance of medulloblastoma tumour survivors related to the
area of cerebellum damage.
Rep
Pract Oncol Radiother. 2022 Oct 3;27(6):1037-1044∟.
doi: 10.5603/RPOR.a2022.0105∟.
PMID: 36632295∟.
Observational study. ˍ
Mondragon-Soto M,
Rodríguez-Hernández LA, Moreno Jiménez S,
Gómez Amador JL, Gutierrez-Aceves A, Montano-Tello H,
Reyes-Moreno I, Santos-Zambrano J, Castro-Martinez E,
Gonzalez-Aguilar A.
Clinical,
Therapeutic, and Prognostic Experience in Patients With
Glioblastoma.
Cureus.
2022 Oct 3;14(10):e29856∟.
doi: 10.7759/cureus.29856∟.
PMID: 36381939∟.
Observational study. ˍ
Melnick
K, Miller P, Carmichael E, Wang Y, Tran D, Kresak JL, Ghiaseddin
A, Rahman M.
Histologic
Findings at Time of Repeat Resection Predicts Survival in Patients
with Glioblastoma.
World
Neurosurg. 2022 Oct 4, 2022:S1878-8750(22)01405-X∟.
doi: 10.1016/j.wneu.2022.09.128∟.
PMID: 36206964∟.
Observational study˰ ˍ
Perez JA, Lopez JJ, Torres
Badillo CC, Gill J, Kesari S, Novak P, Temnikov M, Byshovets R,
Bychkov O.
Phase
1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1
(64Zinc Aspartate) in Patients With Cancer and Neurodegenerative
Diseases.
Cureus.
2022 Oct 4;14(10):e2992∟.
doi: 10.7759/cureus.29921∟.
PMID: 36381721∟.
Interventional
study. ˍ
Erratum
in: Cureus.
2022 Oct 14;14(10):c78∟.
doi: 10.7759/cureus.c78∟.
PMID: 36397903∟.
Correction. ˍ
Calabrese
E, Villanueva-Meyer JE, Rudie JD, Rauschecker AM, Baid U, Bakas S,
Cha S, Mongan JT, Hess CP.
The
University of California San Francisco Preoperative Diffuse Glioma
MRI Dataset.
Radiol
Artif Intell. 2022 Oct 5;4(6):e220058∟.
doi: 10.1148/ryai.220058∟.
PMID: 36523646∟.
Observational study. ˍ
Cioffi
G, Waite KA, Edelson JL, Kruchko C, Ostrom QT, Barnholtz-Sloan
JS.
Changes
in survival over time for primary brain and other CNS tumors in
the United States, 2004-2017.
J
Neurooncol. 2022 Oct 5∟.
doi: 10.1007/s11060-022-04138-w∟.
PMID: 36198894∟.
Observational study. ˍ
Ostrom
QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C,
Barnholtz-Sloan JS.
CBTRUS
Statistical Report: Primary Brain and Other Central Nervous System
Tumors Diagnosed in the United States in 2015-2019.
Neuro
Oncol. 2022 Oct 5;24(Supplement_5):v1-v95∟.
doi: 10.1093/neuonc/noac202∟.
PMID: 36196752∟.
Observational study. ˍ
Lu
G, Zhu P, Rao M, Linendoll N, Buja LM, Bhattacharjee MB, Brown RE,
Ballester LY, Tian X, Pilichowska M, Wu JK, Hergenroeder GW, Glass
WF, Chen L, Zhang R, Pillai AK, Hunter RL, Zhu JJ.
Postmortem
study of organ-specific toxicity in glioblastoma patients treated
with a combination of temozolomide, irinotecan and bevacizumab.
J
Neurooncol. 2022 Oct 6∟.
doi: 10.1007/s11060-022-04144-y∟.
PMID: 36203027∟.
Laboratory investigation˰ ˍ
Nair
SK, Botros D, Chakravarti S, Mao Y, Wu E, Lu B, Liu S, Elshareif
M, Jackson CM, Gallia GL, Bettegowda C, Weingart J, Brem H,
Mukherjee D.
Predictors
of surgical site infection in glioblastoma patients undergoing
craniotomy for tumor resection.
J
Neurosurg. 2022 Oct 7, 2022:1-8∟.
doi: 10.3171/2022.8.JNS212799∟.
PMID: 36208433∟.
Observational study˰ ˍ
Munjapara V,
Heumann T, Schreck KC, Gross JM, Perez-Heydrich C, Gujar SK,
Eberhart CG, Holdhoff M.
BRAF
V600E-Mutant Glioblastoma with Extracranial Metastases Responsive
to Combined BRAF and MEK Targeted Inhibition: A Case Report.
Case
Rep Oncol. 2022 Oct 7;15(3):909-917∟.
doi: 10.1159/000525660∟.
PMID: 36825105∟.
Case report. ˍ
Nitta
RT, Luo EJ, Lim M, Li G.
Can
tumor treating fields induce DNA damage and reduce cell motility
in medulloblastoma cell lines?
J
Neurosurg Pediatr. 2022 Oct 7, 2022:1-12∟.
doi: 10.3171/2022.8.PEDS22300∟.
PMID: 36208441∟.
Laboratory investigation˰ ˍ
Gherasim-Morogai
N, Afrasanie VA, Gafton B, Marinca MV, Alexa-Stratulat T.
Can
Extended Chemotherapy Improve Glioblastoma Outcomes? A
Retrospective Analysis of Survival in Real-World Patients.
J
Pers Med. 2022 Oct 8;12(10):1670∟.
doi: 10.3390/jpm12101670∟.
PMID: 36294809∟.
Observational study. ˍ
He
D, Wu P, Li G, Zhu S, Wang Q, Shao Q, Chang H.
Association
between a prior cancer history and prognosis in adult patients
with high‑grade glioma.
J
Clin Neurosci. 2022 Oct 11;106:20-26∟.
doi: 10.1016/j.jocn.2022.09.017∟.
PMID:
36240544∟.
Observational study˰ ˍ
Spinazzi
EF, Argenziano MG, Upadhyayula PS, Banu MA, Neira JA, Higgins DMO,
Wu PB, Pereira B, Mahajan A, Humala N, Al-Dalahmah O, Zhao W, Save
AV, Gill BJA, Boyett DM, Marie T, Furnari JL, Sudhakar TD, Stopka
SA, Regan MS, Catania V, Good L, Zacharoulis S, Behl M, Petridis
P, Jambawalikar S, Mintz A, Lignelli A, Agar NYR, Sims PA, Welch
MR, Lassman AB, Iwamoto FM, D'Amico RS, Grinband J, Canoll P,
Bruce JN.
Chronic
convection-enhanced delivery of topotecan for patients with
recurrent glioblastoma: a first-in-patient, single-centre,
single-arm, phase 1b trial.
Lancet
Oncol. 2022 Oct 12, 2022:S1470-2045(22)00599-X∟.
doi: 10.1016/S1470-2045(22)00599-X∟.
PMID: 36243020∟.
Interventional study˰ ˍ
Hallan DR, Tankam CS, Harbaugh
T, Rizk E.
Risk
of Glioblastoma Multiforme in Patients Taking Ion Channel
Blockers.
Cureus.
2022 Oct 13;14(10):e30277∟.
doi: 10.7759/cureus.30277∟.
PMID: 36381874∟.
Observational study. ˍ
Semyachkina-Glushkovskaya
O, Diduk S, Anna E, Elina D, Artem K, Khorovodov A, Shirokov A,
Fedosov I, Dubrovsky A, Blokhina I, Terskov A, Navolokin N,
Evsukova A, Elovenko D, Adushkina V, Kurths J.
Music
improves the therapeutic effects of bevacizumab in rats with
glioblastoma: Modulation of drug distribution to the brain.
Front
Oncol. 2022 Oct 13;12:1010188∟.
doi: 10.3389/fonc.2022.1010188∟.
PMID: 36313687∟.
Laboratory investigation. ˍ
Laigle-Donadey
F, Metellus P, Guyotat J, Menei P, Proust F, Dufour H, Chinot O,
Honnorat J, Faillot T, Paquis P, Peruzzi P, Emery E, Guillamo JS,
Carpentier A, Wager M, Lebbah S, Hajage D, Delattre JY, Cornu P;
ANOCEF-IGCNO.
Surgery
for glioblastomas in the elderly: an Association des
Neuro-oncologues d'Expression Française (ANOCEF) trial.
J
Neurosurg. 2022 Oct 14, 2022:1-7∟.
doi: 10.3171/2022.8.JNS221068∟.
PMID: 36242578∟.
Interventional study˰ ˍ
Rooney AG, Hewins W, Walker A,
Mackinnon M, Withington L, Robson S, Torrens C, Hopcroft LEM,
Clark A, Anderson G, Bulbeck H, Dunlop J, Welsh M, Dyson A,
Emerson J, Cochrane C, Hill R, Carruthers J, Day J, Gillespie D,
Hewitt C, Molinari E, Wells M, McBain C, Chalmers AJ, Grant
R.
Lifestyle
coaching is feasible in fatigued brain tumor patients: A phase
I/feasibility, multi-center, mixed-methods randomized controlled
trial.
Neurooncol
Pract. 2022 Oct 14;10(3):249-260∟.
doi: 10.1093/nop/npac086∟.
PMID: 37188163∟.
Interventional study. ˍ
Wang
Y, Wang Z, Hua C, Xu Y, Li Y, Zhao G.
Primary
malignant brain tumors following systemic malignancies: a
population-based analysis.
Neuroepidemiology.
2022 Oct 14∟.
doi: 10.1159/000527437∟.
PMID: 36244332∟.
Observational study. ˍ
Zhu
JJ, Goldlust SA, Kleinberg LR, Honnorat J, Oberheim Bush NA, Ram
Z.
Tumor
Treating Fields (TTFields) therapy vs physicians' choice
standard-of-care treatment in patients with recurrent
glioblastoma: a post-approval registry study (EF-19).
Discov
Oncol. 2022 Oct 14;13(1):105∟.
doi: 10.1007/s12672-022-00555-5∟.
PMID: 36239858∟.
Observational study. ˍ
Kim M, Park JE, Yoon SK, Kim N, Kim
YH, Kim JH, Kim HS.
Vessel
size and perfusion-derived vascular habitat refines prediction of
treatment failure to bevacizumab in recurrent glioblastomas:
validation in a prospective cohort.
Eur
Radiol. 2022 Oct 15∟.
doi: 10.1007/s00330-022-09164-w∟.
PMID: 36242633∟.
Interventional study˰ ˍ